Good morning :)
Place Order
Add to Watchlist
Home
Portfolio
Search
GoldGold
More

Jenburkt Pharmaceuticals Ltd

JENBURPH

Jenburkt Pharmaceuticals Ltd

JENBURPH
Health CarePharmaceuticals
SmallcapWith a market cap of ₹552 cr, stock is ranked 1,792
High RiskStock is 3.09x as volatile as Nifty
1,252.953.62% (-47.10)
1,252.953.62% (-47.10)

Price Chart

High
—
Low
—
Returns
—
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
SmallcapWith a market cap of ₹552 cr, stock is ranked 1,792
High RiskStock is 3.09x as volatile as Nifty

How to use scorecard? Learn more

Health CarePharmaceuticals
SmallcapWith a market cap of ₹552 cr, stock is ranked 1,792
High RiskStock is 3.09x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
18.263.821.22%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
51.276.550.51%

Forecast & Ratings

Detailed Forecast 
—
Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Jenburkt Pharmaceuticals Limited is engaged in the manufacture of pharmaceutical formulations. The Company offers prescription and over-the-counter drugs.

Peers

Compare with peers 
Compare with Peers

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Price Forecast

Hmm, looks like data is unavailable here. Please come back after some time

Revenue Forecast

Hmm, looks like data is unavailable here. Please come back after some time

Earnings Per Share Forecast

Hmm, looks like data is unavailable here. Please come back after some time

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Lower than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 3.07%, vs industry avg of 9.03%

Decreasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share decreased from 0.06% to 0.04%

Lower than Industry Net Income

Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 5.59%, vs industry avg of 15.28%

Loading...

Financial YearFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue96.32106.27118.06126.05123.11113.60128.93141.87146.64154.05
Raw Materialssubtract28.8932.5130.5138.7533.5526.9133.7231.6730.80110.50
Power & Fuel Costsubtract0.570.530.610.590.590.500.610.760.75
Employee Costsubtract21.4925.2127.6931.2036.5132.3836.4938.8142.49
Selling & Administrative Expensessubtract26.1126.6127.3028.1025.4623.0324.3229.0331.04
Operating & Other expensessubtract0.07-1.274.78-0.953.036.621.596.123.77
Depreciation/Amortizationsubtract1.991.791.501.352.302.041.902.262.342.41
Interest & Other Itemssubtract0.380.410.410.390.530.470.430.370.270.36
Taxes & Other Itemssubtract6.056.978.056.836.275.147.588.259.2010.49
EPS23.1629.0637.2643.1232.4035.9748.5754.6558.8768.63
DPS7.208.109.0010.208.1010.2012.0014.4015.3015.30
Payout ratio0.310.280.240.240.250.280.250.260.260.22
See Costs

EPS and DPS in ₹. Other numbers except Payout Ratio in ₹ cr

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2020

Annual report

PDF
FY 2021

Annual report

PDF
FY 2022

Annual report

PDF
FY 2023

Annual report

PDF
FY 2024

Annual report

PDF
 

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Valuation

Technical

Forecast

ScreenerCompare valuation on Screener

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Jenburkt Pharmaceuticals Ltd21.283.821.22%
Sun Pharmaceutical Industries Ltd45.346.470.75%
Cipla Ltd31.214.800.82%
Torrent Pharmaceuticals Ltd65.3815.800.88%

Price Comparison

Compare JENBURPH with any stock or ETF
Compare JENBURPH with any stock or ETF
JENBURPH
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding46.71%0.00%0.00%0.00%53.29%

Dec 2023

Mar 2024

Jun 2024

Sep 2024

Shareholding History

JunSepDec '23MarJunSep1.79%1.38%0.00%0.00%0.00%0.00%

Insider Trades & Bulk Deals

Loading...

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

Increasing Dividends

Dividends are the portion of earnings that a company distributes to all its shareholders every year

JENBURPH has increased dividends consistently over the last 5 years

Dividend Yield

Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation

Current dividend yield is 1.24%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹12.42 every year

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateJul 23, 2024

Final
Final | Div/Share: ₹15.30

Dividend/Share

₹15.30

Ex DateEx Date

Jul 23, 2024

Cash Dividend

Ex DateEx DateJul 19, 2023

Final
Final | Div/Share: ₹14.40

Dividend/Share

₹14.40

Ex DateEx Date

Jul 19, 2023

Cash Dividend

Ex DateEx DateJul 21, 2022

Final
Final | Div/Share: ₹12.00

Dividend/Share

₹12.00

Ex DateEx Date

Jul 21, 2022

Cash Dividend

Ex DateEx DateAug 30, 2021

Final
Final | Div/Share: ₹10.20

Dividend/Share

₹10.20

Ex DateEx Date

Aug 30, 2021

Cash Dividend

Ex DateEx DateMar 18, 2020

Interim
Interim | Div/Share: ₹8.10

Dividend/Share

₹8.10

Ex DateEx Date

Mar 18, 2020

News & Opinions
Earnings
Jenburkt Pharmaceuticals standalone net profit rises 31.15% in the September 2024 quarter

Net profit of Jenburkt Pharmaceuticals rose 31.15% to Rs 9.60 crore in the quarter ended September 2024 as against Rs 7.32 crore during the previous quarter ended September 2023. Sales rose 7.65% to Rs 41.22 crore in the quarter ended September 2024 as against Rs 38.29 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales41.2238.29 8 OPM %27.7323.77 - PBDT13.1610.13 30 PBT12.529.54 31 NP9.607.32 31 Powered by Capital Market - Live

3 days agoCapital Market - Live
Corporate
Jenburkt Pharmaceuticals to announce Quarterly Result

Jenburkt Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 5 November 2024Powered by Capital Market - Live

1 week agoCapital Market - Live

Jenburkt Pharmaceuticals standalone net profit rises 38.18% in the June 2024 quarter

3 months agoBusiness Standard
Earnings
Jenburkt Pharmaceuticals standalone net profit rises 38.18% in the June 2024 quarter

Net profit of Jenburkt Pharmaceuticals rose 38.18% to Rs 7.42 crore in the quarter ended June 2024 as against Rs 5.37 crore during the previous quarter ended June 2023. Sales rose 11.51% to Rs 32.54 crore in the quarter ended June 2024 as against Rs 29.18 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales32.5429.18 12 OPM %28.5523.85 - PBDT10.597.93 34 PBT10.077.43 36 NP7.425.37 38 Powered by Capital Market - Live

3 months agoCapital Market - Live
Corporate
Jenburkt Pharmaceuticals to declare Quarterly Result

Jenburkt Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 26 July 2024.Powered by Capital Market - Live

3 months agoCapital Market - Live

Pharma stock declares ₹702 share buyback at a premium of 13%

1 year agoLivemint

Dividend paying pharma stock to consider share buyback

1 year agoLivemint

Jenburkt Pharmaceuticals standalone net profit rises 40.56% in the September 2021 quarter

3 years agoBusiness Standard

Jenburkt Pharmaceuticals standalone net profit declines 16.02% in the March 2021 quarter

3 years agoBusiness Standard

Stocks in news: ITC, Infosys, PVR, MTAR Tech, SBI, Panacea Biotec and Radico Khaitan

3 years agoEconomic Times